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INVESTIGATING THE BALANCE BETWEEN ESTROGEN RECEPTOR 
MEDIATED CELL PROLIFERATION AND GENOMIC SURVEILLANCE  
SEPTEMBER 2016 
MARGARITA M. BROWN, B.A., MOUNT HOLYOKE COLLEGE 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Dr. Karen A. Dunphy 
Breast cancer is a leading cause of cancer in women and the second leading 
cause of cancer death. Lifetime exposure to estrogen contributes to this risk but 
high dose estrogen has been used to induce apoptosis as treatment for breast 
cancer. These opposing tumorigenic and anti-tumorigenic effects of estrogen 
may be regulated differently by the two Estrogen Receptors (ER), Estrogen 
Receptor alpha (ERα) and Estrogen Receptor beta (ERβ). Although the receptors 
share a 96% homology in their DNA binding domain, they are unique in the 
ligand-binding domain with 53% amino acid homology. Previous studies have 
shown that ERα drives cell proliferation in the mammary gland. We propose that 
ERβ mediates genomic surveillance in the mammary gland to restrict 
proliferation. To test this hypothesis we first characterized each of our reference 
breast cancer cell lines to determine the ERα and ERβstatus. We found that ERβ 
transcript and protein are expressed in some breast cancer cell lines that are 




ER agonists, we were able to demonstrate that amphiregulin, a secreted protein 
and a marker of ERα activation, is upregulated by ERα agonists in a dose 
dependent manner in cell lines that have ERα (T47D & MCF7). ERα agonists do 
not enhance AREG expression in cell lines that primarily expresses ERβ 
(HCC1937). Instead,  CEBPd, a tumor suppressor, is expressed at high levels in 
this cell line. In conclusion, targeting ERβ has the potential to selectively activate 
tumor suppressor pathways without stimulating proliferation and may provide a 
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The Dual Roles of Estrogen 
 
 Globally, the most common cancer in women is breast cancer. In the 
United States, the probability of a woman developing breast cancer in her 
lifespan is 1 in 8 (Siegel, 2015). Although many factors play a role in the 
occurrence of cancer, including a woman’s genetics and lifestyle choices, the 
greatest contribution to breast cancer risk in a lifetime stems from chronic 
exposure to estrogen (K. N. Anderson, Schwab, & Martinez, 2014). 
Estrogen has duplicitous effects in the breast, in that it both promotes and 
reduces breast cancer risk (Folkerd E, 2013). Early menarche, late menopause 
and estrogen exposure post-menopause promote breast cancer risk, while an 
early full term pregnancy reduces that risk by 50% (MacMahon et al., 1970). In 
vivo studies in rats using estrogen and progesterone to mimic levels during 
pregnancy showed a reduction in the incidence of mammary tumors (Cabanes et 
al., 2004; Rajkumar et al., 2001; Sivaraman et al., 1998). Also, parous and 
hormone treated mice had a greater apoptotic response to ionizing radiation 
compared to nulliparous mice (Dunphy KA, 2008). High doses of estrogen have 
also been used successfully to treat breast cancer in postmenopausal women by 





Ellis et al., 2009; Haddow, Watkinson, Paterson, & Koller, 1944). These dual 
roles indicate a potential balance between estrogen-mediated pathways that 
regulate proliferation versus genomic surveillance facilitated by cell cycle arrest 
and apoptosis.  The opposition of effects between activation and abatement of 
proliferation might be regulated by different estrogen receptors in order to 
maintain the homeostatic balance within the mammary epithelium.  
Estrogen signals via two receptors, Estrogen receptor alpha (ERα) and 
Estrogen receptor beta (ERβ), to regulate gene transcription (Gruber, Gruber, 
Gruber, Wieser, & Huber, 2004). Two ligand bound estrogen receptors located in 
the nucleus dimerize and bind to an estrogen response element (ERE) on DNA.  
Recruitment of co-activators and co-repressors interacting with the DNA bound 
estrogen receptor-ligand complex assist in transcription regulation in tissues 
(Kurebayashi et al., 2000). Estrogen receptors can homodimerize forming an 
ERα-ERα or ERβ-ERβ complex; or they can heterodimerize as ERα-ERβ 
(Ogawa et al., 1998). Dimerization of the different homodimers and heterodimers 
could elicit different effects in the regulation and transcription of genes (Monroe 
et al., 2005).  
Two separate genes, ESR1 and ESR2, encode ERα and ERβ 
respectively. Estrogen receptors have four functional domains and a hinge region 
(Figure 1.1). The N-terminal domain (A/B) is regulatory, and contains an 
activation function region (AF-1) that coordinates the receptors interaction with 




domain (C/D) is highly conserved between both ERα and ERβ and the receptors 
share a 96% conserved region that binds to the hormone response element on 
DNA. The hinge region (D) gives the receptor flexibility between the DNA binding 
domain and ligand binding domain. The E/F domain contains both the ligand 
binding pocket and the AF-2 region that directly contacts coactivator peptides. 
The function of the F domain on the C-terminal is still being investigated.  Though 
the two ERs are similar in their DNA binding region, they are distinct in their 
ligand-binding domain with only 53% homology (Reese et al., 2014). Because the 
DNA binding domain is highly conserved (96%) between ERα and ERβ, both 
receptors have similar affinity for the ERE (Klinge, 2001).  However, because the 
ligand-binding domain is distinct (53%) between ERα and ERβ, this region 
confers ligand specificity to each receptor that can be used to stimulate one 
receptor and not the other.   
ERα and ERβ have distinct tissue expression patterns in different tissues 
of the body. Regionally, ERα is expressed in the pituitary gland and the uterus 
while ERβ is predominately found in the lungs and the bladder. Both receptors 
are expressed in the normal mammary gland (Mueller & Korach, 2001). ERα is 
expressed in 15-30% of luminal epithelial cells while ERβ is expressed in luminal 
epithelial, myoepithelial, fibroblasts and adipocytes (Figure 1.2)(Anderson, 2002). 
Interestingly, ER positive status is lost during cancer progression and in many 
breast cancer cell lines (Park P 2001, Shaaban AM 2003, Roger P 2001, Bardin 




of human breast cancer tumors (V. Speirs, 1998). Confirming ERα and ERβ 
status in ER positive cell lines:  T47D, MCF-7, ZR 75-1, 76N TERT and in ER 
negative cell lines:  MDA 231 and HCC1937, as well as assessment of an ERβ 
inducible cell line: MCF-7 –tetracycline-repressible ERβ (MTO ERβ), will 
cumulatively be powerful in vitro tools for the assessment of growth responses 
based on ER ratios (Figure 1.3).  
Both receptors bind 17β-estradiol (E2), the endogenous ligand, with an 
equal affinity (Figure 1.4). Estrogen receptor ligands with specific affinities for 
ERα or ERβ exist. All estrogen receptor agonists are measured in relation to the 
competitive binding between E2 and the competitor. The ERα specific ligand, 
Propyl-pyrazole-triol (PPT) shows >410-fold selectivity for ERα over ERβ. 
Whereas 7-Ethenyl-2- (3-fluoro-4-hydroxyphenyl)-5-benzoxazolol (ERB041) and 
Diarylpropionitrile (DPN) display >200-fold and 70-fold selectivity for ERβ over 
ERα, respectively (Kuiper et al., 1997).  Using ER specific ligands to bind to 
either ERα or ERβ will give us the ability to examine the distinct transcriptional 
properties of the receptors in the context of the different cell lines. 
Estrogen receptor selective agonists have been used in the past to study 
both the balance of ERα and ERβ in cell lines as well as the expression of their 
target genes. One study used a tetracycline inducible ERβ variant of the human 
osteosarcoma line (U2OS) to measure how the ratio of ERα and ERβ effected 
cell proliferation induced by E2, the ERα agonists PPT, and the ERβ agonist 




agonist DPN corresponded to curbed cell proliferation when compared to cells 
treated with E2. Also, they found that the addition of the ERα agonist PPT to the 
cells, regardless of ER expression, would stimulate cell proliferation (Sotoca et 
al., 2008).  Another study used the breast cancer cell line MCF-7 to investigate 
the transcriptional profiles of ERα and ERβ stimulation. MCF-7 cells that were 
treated with E2 were shown to up regulate genes that signal for cellular 
proliferation including Amphiregulin (AREG) while simultaneously down 
regulating Transforming growth factor beta (TGFβ), a cytokine that restricts cell 
growth (Frasor et al., 2003). An additional study found that ERβ specific 
stimulation by DPN increases the PTEN tumor suppressor in MCF-7 and T47D 
breast cancer cell lines (Lindberg, Helguero, Omoto, Gustafsson, & Haldosen, 
2011). This indicates that there are specific estrogen receptor roles in the 
regulation of cell proliferation.  
Breast cancer is grouped by receptor status through immunohistological 
(IHC) characterization.  Broadly, breast tissues stain positively for estrogen 
receptor alpha (ERα+) and progesterone receptor (PR+) are classified as 
“Receptor Positive” or “Luminal Type” breast cancer. Currently, therapeutics that 
antagonize the estrogen receptor exist and prognosis is generally good. Targeted 
therapeutics are also available for breast cancers that stain positively for HER-
2/neu (HER-2+). Unfortunately, 15% of breast cancers do not stain for any 
receptor and are classified as triple negative breast cancer (TNBC)(Chacón & 




because there are no targeted treatments available. Though both ERα and ERβ 
are expressed in the mammary gland (Kuiper GG, 2007), only ERα is routinely 
tested for (Allred, 2010). However, the ER content of breast tumors that were 
categorized as triple negative (TNBC) has been investigated and it was 
determined that up to 25% of TNBCs expressed ERβ (Reese et al., 2014). 
Therefore, ERβ targeted therapy is a potential option to elicit a genomic 
surveillance response and cell cycle arrest in TNBC.  
The dual roles for estrogens and their contribution to genomic surveillance 
and proliferation have been investigated previously in the Jerry lab.  BALB/c-
Trp53+/+ mice were ovariectomized and allowed to recover and clear endogenous 
hormones for one week. They received daily intraperitoneal injections for 4 days 
with vehicle, E2 (2ug), progesterone (P; 200ug) and an E2+P combination and 
were subjected to 5Gy ionizing radiation prior to tissue harvest (Becker et al., 
2005). Nuclear protein expression of radiation-induced p21, a cell cycle inhibitor, 
was upregulated to the greatest extent in the E2 or E2+P treatment groups 
compared to vehicle and P alone. Furthermore, treatment with E2+P + ICI 
182,780 (an estrogen receptor inhibitor) mirrored the lower radiation-induced p21 
response to progesterone alone.  E2+P +mifepristone (an inhibitor of 
progesterone receptor) retained a strong p21 response to ionizing radiation. This 
indicated that the estrogen receptor was necessary to fully potentiate radiation-




To examine the contribution of the two estrogen receptors, ERα and ERβ, 
in terms of proliferation and genomic surveillance responses, ovariectomized 
BALB/c mice were implanted with silastic capsules containing cellulose (Control) 
or cellulose with Progesterone (20mg) together with E2 (50ug), or one of the ER 
selective agonists: for ERα - PPT (400ug) and for ERβ - DPN (400ug) (Erick 
Roman-Perez, unpublished. After 3 days, mice were subjected to ionizing 
radiation. Apoptotic responses were increased to a similar extent by all hormones 
when compared to control (Figure 1.5a). However, the only E2+P and PPT+P 
increased proliferation as determined by BrdU incorporation and amphiregulin 
expression (Figure 1.5b).  The ERβ agonist, DPN failed to activate proliferation. 
Roman-Perez et al concluded that the ERβ specific agonists (DPN) could 
activate genomic surveillance via induction of apoptosis in response to radiation 
without inducing proliferation.     
Hypothesis and Rationale  
 
Estrogen bound to an Estrogen Receptor can stimulate proliferation and to 
enhance genomic surveillance to prevent the unwanted proliferation of damaged 
cells. These dual roles are central to the paradox of estrogen- the ability of 
estrogen to both promote and inhibit breast cancers. This is possibly due to the 
ratio of the two estrogen receptors, alpha and beta, and their ability to balance 
estrogen-mediated proliferation with genomic surveillance to activate apoptosis 
or cell cycle arrest. The two estrogen receptors are 96% homologous in their 




elements on DNA, but are distinctive in their ligand-binding domain with 53% 
amino acid homology. This means that the two different estrogen receptors can 
be selectively targeted with selective estrogen receptor agonists.  
Specific estrogen receptor agonists have been used in the past to 
compare Estrogen Receptor responses in vitro using human breast cancer cell 
lines and in vivo using mouse models. Preliminary data in mice show that 
radiation induced apoptosis is increased with estrogen receptor agonists 
(Roman-Perez, unpublished). Only the ERβ specific agonist could induce 
apoptosis without activating proliferation.  
Hypothesis: Specific activation of ERβ in the human mammary gland selectively 
activates genes that mediate genomic surveillance without stimulating 
proliferation.  
Several Estrogen Receptor targets are of interest to breast cancer 
research because of their association with cell proliferation or genomic 
surveillance (Figure 1.6). The ERα associated protein amphiregulin (AREG) is of 
interest because it is an effector of estrogen signals and it works in a paracrine 
fashion to promote growth in neighboring epithelial cells (Peterson et al., 2015). A 
second target of interest is the Progesterone Receptor (PR) which is positively 
regulated by ERα ligand-dependent activation (Lin et al., 2004).  
ERβ mediated growth restriction may occur by regulating the expression 
of cytokines and transcription factors. One cytokine of interest that may be 




estrogen stimulated growth repressor that has been suggested to be regulated by 
ERβ in rat prostates (Itoh, Patel, Cupp, & Skinner, 1998). The transcription factor 
CCAAT/Enhancer Binding Protein (CEBPD) is also of interest because it is 
expressed in mammary luminal epithelial cells during involution and co-regulates 
pro-apoptotic genes (Thangaraju et al., 2005; Yu, Si, Zhang, & DeWille, 2010).  
Investigating the targets of Estrogen Receptors may help elucidate the molecular 
events that govern breast cancer cell proliferation and genomic surveillance.  
Targeting a hormone receptor has been a successful therapy for breast 
cancer for patients who test positive for ERα, PR or Her2. Current targeted 
therapies for Estrogen Receptor positive breast cancer aim to inhibit the 
proliferative effects of ERα. There are no targeted therapies for Triple Negative 
Breast Cancer (TNBCs), which lack ERα, progesterone receptor (PGR) and 
human epidermal growth factor receptor 2 (HER2). TNBCs have poor prognosis. 
However, some TNBCs express ERβ. Targeting ERβ has the potential to 
selectively activate surveillance pathways without stimulating proliferation and 
may provide a treatment option for patients for whom inhibition of ERα is not an 
option (both ERα+ non-responders and TNBCs).  Further, the expression of a 
higher ratio of ERβ to ERα may be important to an increased disease-free and 
overall survival in patients with triple negative breast cancer (Honma et al., 2008). 








Objective 1. Characterize the ratios of ERα and ERβ in cell lines by gene 
and protein expression. 
Luminal type: MCF-7, T47D, ZR75-1, MTO ERβ 
Triple negative breast cancer: MDA-MB-231, HCC 1937 
 “Normal”: 76N Tert 
Objective 2: Compare responses to different estrogen receptor agonists in 
breast cancer cell lines in vitro. 
• Cell proliferation measured against cell death  
• Gene expression of proliferation genes vs. surveillance genes 
Objective 3: Conduct an in vivo experiment using the βERKO mouse model 
to explicate the histologic and gene expression profiles of acute agonist 








Adapted fron Roman-Blas, J. A., Casteneda , S., Largo, R., & Herrero-
Beaumont, G. (2009). Osteoarthritis associated with estrogen 
deficiency. Arthritis Res Ther, 11(5), 241. 	
Figure 1.1 Structure and Homology of the Estrogen Receptors.  
Estrogen Receptor alpha (ERα) and Estrogen Receptor beta (ERβ). ERα 
and ERβ share a 96% amino acid homology in their DNA binding domain 
(DBD). They are distinctive in their activation function domain (AF-1, 30% 
homology), hinge domain (D; 30% homology) and in their ligand-binding 
domain (LBD/AF-2; E/F; 53% homology). The differences in these domains 
confer both ligand binding specificity as well as distinct transactivation 
functions to the receptors, allowing for the recruitment of transcription 





Figure 1.2 Expression of ERβ in human mammary gland. 
Immunohistochemistry (IHC) of a human mammary gland using 14C8 ERβ 
antibody shows that ERβ is expressed in fibroblasts (a), myoepithelial cells 
(b), luminal cells (c) and adipocytes (d).  	
 	








Figure 1.3 Table of Breast Cancer Cell Line Characteristics.
Soussi, Thierry. "Handbook of p53 mutation in cell lines." Version 
1, no. 07 (2007): 2007.
  	
	
Cell Line ER PR Her2 P53 
T47D + + + leu to phe   
MCF-7  + + + wt 
MDA MB 231 - - - arg to lys 
MCF-7 MTO ERB Repressed + + + wt 
HCC1937 - - - mutant (stop) 
ZR75-1 + + + wt 
76N tert + +  n/a  wt  
MCF-7 MTO ERB Expressed + + + wt 






Figure 1.4 Estrogen Receptor Agonists.  Endogenous and 
exogenous ligands for the estrogen receptor and their relative binding 
































Figure 1.5 Proliferation and Apoptosis in the BALB/c Mouse 
Mammary Gland in Response to Agonists.  Estrogen receptor 
agonists 17β-estradiol (E), 4,4',4''-(4-Propyl-[1H]-pyrazole-1,3,5-
triyl)trisphenol (PPT) and Diarylpropionitrile  (DPN) increase 
radiation induced apoptosis response in BALBc mice when 
combined with progesterone (P) to mimic the protective effect of 
parity (a), but only 17β-estradiol and PPT induce proliferation 
(b), DPN a potent Estrogen Receptor β agonist failed to induce 
proliferation. 	
 	

































Figure 1.6 Model depicting hypothesis whereby estradiol 
stimulates proliferation or genomic surveillance by regulating 









CHARACTERIZATION OF THE RATIOS OF ERα AND ERβ IN CELL LINES BY 
GENE AND PROTEIN EXPRESSION 
Introduction/Rationale 
 
Examining the expression of ERα and ERβ across cell lines is important 
because there are conflicts with regard to the ER status of human breast cancer 
cell lines in the literature (Figure 2.1 a&b). For example, the MCF-7 cell line is 
regarded as a model of an exclusively ERα positive cell line (Felzen et al., 2015; 
Hsieh, Santell, Haslam, & Helferich, 1998). Yet some report that the MCF-7cell 
line also expressed ERβ (Tong et al., 2002; Vladusic, Hornby, Guerra-Vladusic, 
Lakins, & Lupu, 2000). Further, the MDA MB 231 cell line is used as a model for 
ER negative breast cancers (Price, Polyzos, Dan Zhang, & Daniels, 1990) and 
published data from three sources, using both RT-PCR and western blot assays, 
find that the MDA MB 231 cell line, are, in fact, ERα negative (Kao et al., 2009; 
Subik et al., 2010; Tong et al., 2002). However, other published reports 
demonstrate that MDA MB 231 is both ERα (Ford, Al-Bader, Al-Ayadhi, & 
Francis, 2011) and ERβ positive (Ford et al., 2011; Tong et al., 2002). 
Establishing ER status in our reference cell lines is necessary for the examination 
of the ER agonist responses. The selected human cell lines represent “normal” 
breast epithelium (76N Tert), luminal type breast cancers (MCF-7, T47D, ZR75-1, 




receptors, expression of ESR1 and ESR2, the genes for ERα and ERβ 
respectively, will be assessed using qPCR and protein will be evaluated with 
western blots. Primers for qPCR amplification are included in Figure 2.2.  
Detection of ERα expression was accomplished using the historically 
validated antibody SC-542 (MC-20), a polyclonal rabbit ERα antibody from Santa 
Cruz (Karen A. Dunphy et al., 2013). Immunohistochemical and western blot 
detection of ERβ has been unreliable in the past because the available 
antibodies are inconsistent (Skliris et al., 2002). Recently, a paper from the 
Mercurio lab at UMass Medical School investigated how the loss of ERβ effected 
chronic inflammation in human prostates (Mak, Li, Samanta, & Mercurio, 2015). 
They used the GeneTex ERβ antibody GTX112927 to observe ERβ expression in 
prostate cell lines. This rabbit polyclonal antibody was made against a 
recombinant peptide sequence within the center region of human ERβ (Figure 
2.3). Additionally, because western blot detection and specificity of ERβ 
antibodies have been inconsistent in the past, we will also consider the primary 
antibodies GTX70174 (GeneTex) mouse monoclonal antibody, clone 14C8, 
developed against aa 1-153 of human ERβ, PA1-311 (Thermo Scientific) rabbit 
polyclonal, immunogen aa 55-70 of rat ERβ and PA1-310B (Thermo Scientific) 
rabbit polyclonal, immunogen aa 467-485 as potential options for assessing ERβ 
expression in human cell lines (Figure 2.3).   
There are five described isoforms of ERβ, of which only ERβ1 contains a 




Hassan, & Ho, 2006). Three of the antibodies (GTX112927, GTX70174 and PA1-
311) will bind all isoforms of ERβ while only PA1-310B will bind to the unique 
intact C-terminal end of ERβ1 (Figure 2.3). ERβ2, 4 and 5 do not have the ability 
to increase gene activation on their own, they must dimerize with ERβ1. It is 
therefore useful to include primary antibodies that are able to recognize 
functional ERβ1 in this study.  
The efficacy and specificity of the ERβ antibodies will be assessed using 
the inducible ERβ cell line MCF-7 Tet-Off (MTO ERβ) as a positive control. MTO 
ERβ is a human breast cancer derived cell line stably transfected with 
tetracycline repressible estrogen receptor beta.  The cells express a tetracycline 
regulated Tet-Off transactivator. Inducible expression of ERβ occurs when 
doxycycline (dox) is withdrawn from the culture medium. Conversely, in the 
presence of dox, ERβ expression is repressed.  The inducible MTO ERβ is a 
good positive control for ERβ because we can regulate ERβ expression and have 
already determined the doses of doxycycline for efficient repression of ERβ 
(Figure 2.4). As a negative control, the human cervical adenocarcinoma derived 
cell line HeLa, was used, as it is negative for both ERα and ERβ (Holliday & 
Speirs, 2011).  
Materials and Methods 
 
Cell Culture:  T47D and MDA MB 231 cells were kindly donated by Dr. Sallie 
Schneider. MCF-7 tet off cells were provided by  Dr. L. Hodges-Gallagher 




from Dr. Vimla Band, Hela cells from Dr. Rong Shao. HCC1937 were purchased 
from ATCC. All cells were cultured at 37°C and 5% CO2. Each Cell line was 
expanded in their standard Dulbecco’s Modified Eagle’s Medium/Nutrient mixture 
F1-12 Ham (DMEM:F12, Sigma-Aldrich; St. Louis, MO) with 15 mM NaHCO3 and 
25 mM Hepes. Cells were plated in triplicate, either at 500,000 cells/well or 
1,000,000 cells/well in a six well plate (Cell Treat; Shirley, MA) at 50-60% 
confluence in order to achieve optimum 75-80% cell density after 24hrs of 
incubation. The cells were harvested for mRNA (three replicates) or lysates 
(three replicates). To repress the expression of ERβ in the MCF-7 tet off cells, 
cells were maintained in 50 ng/ml Doxycycline (Dox)(Sigma-Aldrich; St. Louis, 
MO). To repress ERα, cells were treated with 10nm ICI 182,780, 10nm E2 or 
both.  
Primer Design and Efficiency Determination:  Oligonucleotide primers were 
designed with software from qPrimerDepot (Dr. Wenwu Cui PhD, National 
Institutes of Health) and analyzed using the Integrated DNA Technologies (IDT) 
OligoAnalyzer software (Redwood City, CA), with sequences available from the 
PubMed database. The primer pairs were selected using the following criteria: 
the cDNA amplicon will be about 100 base pairs, primers are designed to flank 
intron-exon borders or primers that will anneal at a splice junction to distinguish 
genomic DNA from cDNA, primers will have similar annealing temps at or around 
60°C, with a G/C content of 20-70% and low or no self-complementarity 




sequence. Primer efficiency was determined by measurement of the gradient of a 
standard curve. The log of the target concentration was plotted against the 
quantitation cycle. Efficiencies at or close to 100% were accepted.  
mRNA Isolation and RT-qPCR:  RNA was isolated from cell culture using 1 ml 
TRIzol™ reagent (Life Technologies, Carlsbad, CA) per well (6 well plate), 
according to the manufacturer’s instructions. Complementary DNA was 
synthesized using 1 ug of RNA, d(T)23VN(50μM) and ProtoScript II Reverse 
Transcriptase (New England BioLabs Inc., Ipswich, MA). qPCRs were carried out 
in a MJ Research PTC-100 thermal cycler (Bio-Rad; Hercules, California). 
Quantification of each cDNA was achieved using SYBR Green Master Mix 
Reagent (Applied Biosystems; Foster City, CA) in duplicate. Gene expression is 
shown relative to T47D cells treated with 10nM ICI as an inter run calibrator 
(IRC). Relative quantification was performed using a comparative CT method. 
Values shown are relative to the IRC. Ratios of Estrogen Receptors were made 
relative to T47D cells.  
Western Blotting:  Whole cell extracts were lysed using 300μl/well (6 well plate) 
of ice-cold RIPA lyses buffer (50 mM Tris–HCl, pH 8.0; 150 mM NaCl; 1 mM 
EDTA; 1 % Triton X-100; 1 % Sodium deoxycolate; 0.1 % SDS; 1 % protease 
inhibitors (P8340 Sigma-Aldrich; St. Louis, Mo), 1% phosphatase inhibitor 
#2(P5726, Sigma-Aldrich; St. Louis, MO), 1% phosphatase inhibitor #3 (P0044 
Sigma-Aldrich; St. Louis, Mo) (Sigma-Aldrich; St. Louis, MO). Following 




supernatant containing the protein was removed from the cellular debris and 
quantified by the Bradford method. Equal amounts of protein (20 μg) were 
separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE) through 10 % acrylamide under reducing conditions and then blotted onto 
Hydrophobic Polyvinylidene Fluoride (PVDF) membrane (Immobilon-P; Millipore, 
Watford, United Kingdom). The blot was blocked with a 5 % non-fat dry milk in 
TBST (10 mM tris-HCl pH 7.5, 150 mM NaCl, 0.1 % tween-20) for 60 min and 
subsequently incubated overnight at 4 °C with polyclonal anti- ERα (Santa Cruz 
Biotechnology Inc, MC-20: sc-542; 1:1000), anti-ERβ (Thermo Scientific PA1-
311B; 1:2000 PA1-310B; 1:1000; GeneTex GTX70174; 1:1500),  and anti-β actin 
(Sigma A1978; 1:5000). After washing in TBST, the membranes were incubated 
with a horseradish peroxidase-conjugated secondary antibody (1:5000) for 1 h. 
The bands were visualized by enhanced chemiluminescence (100 mM Tris/HCl 
pH 8.5, 250 mM luminol (Sigma,Aldrich; St. Louis, MO), 90 mM p-coumaric acid 
(Sigma-Aldrich; St. Louis, MO), 30%  hydrogen peroxide(Sigma-Aldrich; St. 
Louis, MO), imaged using G:BOX (Synoptics Ltd; Frederick, MD) and quantified 
using GeneTools analysis software from Syngene (Synoptics Ltd; Frederick, 
MD).  The expected molecular weight for the protein product for the western blot 
is 66 kDa for ERα, 59 kDa for ERβ and 42 kDa for the β actin loading control.  All 
cell lines were run in two independent experiments, each cell line band was 





Ratio of ESR2: ESR1 and ERβ: ERα:  Expression was set relative to T47D cells. 
Assuming ESR2: ESR1 and ERβ: ERα is 1:1 in T47D cells, the ratio for each cell 
line were determined. These were calculated by comparing relative values. For 
example ESR2: ESR1 in MCF-7 parental cells: ESR2 0.12/ ESR1 1.13 = 0.106. 
Likewise for ERβ: ERα, this was calculated by comparing relative values in MCF-
7 parental cells: ERβ 1.29/ ERα 0.46 = 2.8.  
Statistics:  A two sided students t-test was used to determine differences relative 
to T47D cells. A p-value <0.05 (*) was considered significant and <0.01 (**) 
considered highly significant. Error bars indicate SEM.  
 
Results 
ESR1 and ESR2 have a distinct expression across cell lines  
 ESR1 and ESR2 expression was evaluated using cDNA generated from 
the RNA harvested from the individually cultured cell lines (Figure 2.5 a&b). 
Expression is relative to T47D cells because they were expected to express both 
ERα and ERβ (Ford et al., 2011). ESR1, encoding Estrogen Receptor alpha, was 
expressed to a similar level in T47D, MCF-7 parental cell line as well as the MTO 
ERβ cell line, regardless of whether ERβ was expressed or repressed. The cell 
line ZR 75-1 and the triple negative cell line HCC1937 had about 50% of the 
ESR1 expression as T47D. The other triple negative cell line, MDA MB 231, had 
very little expression and interestingly the “normal” epithelial cell line, 76N tert, 




ESR2 expression in the ZR 75-1 and the 76N tert cell line is similar to the 
T47D cell line (Figure 2.5b). The triple negative cell lines MDA MB 231 and HCC 
1937 have significantly greater ESR2 expression,  with levels that are  ~9-fold  
and ~12.5-fold, respectively, greater than T47D (p<0.01). The parental MCF-7 
cell line has considerably lower ESR2 expression than T47D , but the decrease is 
not significant. The MCF-7 ERβ repressed cell line has six-fold greater ESR2 
expression when compared to T47D (p<0.01). This is probably due to leaky 
expression of the ESR2 gene, even in the presence of doxycycline. Predictably, 
in the absence of doxycycline, the MCF-7 ERβ expressed cell line had greater 
than 200-fold increase in ESR2 expression compared to T47D. 
Validation of Estrogen receptor beta antibodies  
 
There was a need to evaluate several ERβ antibodies for western blotting. 
The primary antibodies GTX70174, PA1-311 and PA1-310B were evaluated. 
ERβ has a calculated molecular weight of about 55-59 kDa in western blots. The 
antibody from GeneTex, GTX70174, failed to show a band on a western blot.  In 
contrast, a band was visualized with the antibody PA1-311 from Thermo 
Scientific, but the suspicion is that the band was non-specific binding of the 
antibody. Comparison of the band to the Dual Color Precision Plus Protein™ 
Standard (BioRad; Hercules, California) showed a product with a molecular 
weight of 66-69 kDa (Figure 2.6 a). Additionally, product was detected with the 
PA1-311 antibody in the estrogen receptor negative HeLa cells.  The PA1-310B 




transfected with ERβ1 and the T47D cells, but did not detect any product in either 
the ovaries from βERKO mice or in HeLa cells, which are negative for both 
estrogen receptors.  Therefore, we used this PA1-310B antibody to quantify the 
ERβ protein expression in the breast cancer cell lines.  
Relative intensity of Estrogen Receptors Protein 
  
The expression of ERα (MC-20 antibody) and ERβ using the validated 
ERβ antibody PA1-310B were determined for all of the cell lines (Figure 2.7 & 
2.8). The relative intensities of ERα (2.8 a), ERβ (2.8 b) and β-actin (2.8 c) were 
made relative to T47D. Protein expression was not normalized to β-actin, instead 
we relied on accurate quantification via Bradford assay and loading of total 
protein because each cell line could have different composition of cytoskeletal 
elements. Therefore, normalizing protein to β-actin may not reflect true 
expression. Each cell line is quite different in behavior and phenotype, but 
regardless there are no differences in β-actin (Figure 2.7 & 2.8 c). 
Expression of ERα protein was the greatest in the T47D cell line and was 
reduced by about 50% in the MCF-7 parental cells (Figure 2.8 a). The MTO ERβ 
off and on cells had about half to two-thirds less ERα detected than the MCF-7 
parental line, although this difference relative to the parental cell line was not 
significant (0.1 and 0.058). The other ERα positive cell line, ZR75-1 and the 
“normal-like) 76N tert, expressed 3% and 7% of T47D level of ERα. The triple 
negative cell lines MDA MB 231 (2%), HCC1937 (6%) and HeLa (2%) had 




Quantification of the ERβ western blots showed that T47D and MCF-7 had 
the highest peak intensity (Figure 2.8 b). MTO ERβ off and on had nearly equal 
ERβ protein detected, ~70% of MCF-7 parental cells. The triple negative cell 
lines MDA MB 231 and HCC1937 had about half as much ERβ expression as 
T47D. The cell lines ZR75-1, 76N tert and HeLa failed to produce a detectible 
band on the western blot.  
Transcript ratios do not directly correlate to protein ratios or levels in  
breast cancer cell lines 
 
Because ERβ is proposed to modulate the proliferation activity of ERα (Li 
et al., 2004) and relative abundance of the receptor vary in the cell lines, we 
wanted to be able to determine ratios of receptor expression. Our objective is to 
classify the cell lines based on receptor ratios as those that express both 
receptors, or are predominantly ERα-expressing or ERβ-expressing to correlate 
to the estrogen response. Therefore, expression of ESR2: ESR1 transcript, as 
well as ERβ: ERα protein in each cell line was determined. Presuming that 
ESR2: ESR1 and ERβ: ERα were 1:1 in T47D cells, although this is not likely, we 
can determine relative ratios of estrogen receptor transcript and protein in each 
of the other cell lines (Figure 2.9). Although transcript of ESR1 is equal between 
T47D, MCF-7 and MTO cells (Figure 2.5) the expression of ERα is not (Figure 
2.8 a) ESR2 transcript was significantly higher in MDA MB 231, MTO and 
HCC1937 cells, but surprisingly, ERβ protein was not increased. These 




and protein in each cell line. For instance, in MCF-7 cells, the ratio of ESR2: 
ESR1 is 0.11, meaning for each unit of ESR2 (relative to T47D) there are 10 units 
of ESR1 (relative to T47D). However, the MCF-7 ERβ:ERα ratio shows 2.77 
relative units of ERβ to each relative unit of ERα. The MTO ERβ repressed cell 
line ratio shows that there are about 5 units of ESR2 for every 1 unit of ESR1 and 
a little over 3 units of ERβ:ERα relative to T47D. ESR2 transcript in the MTO 
ERβ expressed cell line had over 200 relative units of ESR2: ESR1, yet 
surprisingly, peaked at only 5 units of ERβ to ERα protein relative to T47D. The 
triple negative cell lines MDA 231 and HCC1937 expressed 182.79 and 23.64 
units respectively of ESR2 to ESR1 relative to T47D. ERβ protein levels were 
high compared to T47D at 15. 47 and 7.68 units of ERβ ratio, relative to T47D. 
Based on these relative ratios of ESR2: ESR1 and ERβ: ERα, we have classified 
the cell lines as those that express both receptors (T47D, MCF7, MTO 
repressed); those that express a higher ratio of ERβ: ERα (MTO expressed, 
MDA 231, HCC1937); and those that have poor expression of ERs (ZR75-1 and 
76N tert).  
Effect of ICI on ERα in T47D cells 
 
 In an attempt to modulate ERα expression we used both ICI 182,780 and 
E2 treatment. ICI is known to decrease ERα protein (Oliveira et al., 2003) and 
may stabilize ERβ (Montanaro et al., 2005). ICI and E2 were expected to 
decrease ERα expression. ICI binds to ERα to target it for degradation. E2 




expression. We found that neither ICI nor E2 decreased ERα protein measured 
in T47D cells on a western blot (Figure 2.10 a). Quantification of ERβ did 
demonstrate stabilization of ERβ protein by ICI treatment, but not with E2 or ICI + 
E2 treatment (Figure 2.10 c). Quantification of ERα and β-actin showed no 
significant difference between T47D controls, ICI, E2, or ICI + E2 treatments 
(Figure 2.10 b & d).  
Discussion 
 
It is obvious that mRNA expression and protein expression do no correlate 
with each other. We found that ESR1 expression is equivalent between T47D, 
MCF-7 parental and MTO cells. But ERα protein in the MCF-7 parental line was 
only 50% of the amount of ERα protein relative to T47D. MTO cells were found to 
have only about 20-25% of ERα relative to T47D.  ESR2 expression is 
significantly increased by >6 fold in MTO cells and further increased by greater 
than 200 fold in the MTO cells when expression is relived by removing 
doxycycline relative to T47D. However, ERβ protein expression is nit increased in 
the cell lines relative to T47D cells, even though transcript is abundant.  
Our findings confirm that there is no clear correlation found between 
Estrogen Receptor mRNA and protein expression in breast cancer cell lines. This 
result corroborates with published data in which mRNA expression in thousands 
of genes did not predict corresponding protein levels in MCF-7, MDA MB 231 and 
three other breast cancer cell lines (Cifani, Kirik, Waldemarson, & James, 2015).  




environment in which quantitative RNA levels may be fundamentally detached 
from protein half-life in the cellular environment (Schwanhausser et al., 2011).  
 The published data agrees with our results of positive ERα status in MCF-
7 and T47D cells (Kao et al., 2009; Tong et al., 2002). But the literature differs 
with regard to ERβ expression in MCF-7 and T47D cells (Bulzomi et al., 2012; 
Davies et al., 2004). Our results suggest that both cell lines express ERβ. 
Further, there were two interesting results in regard to the characterization of the 
cell lines. One was that our results show that the ERα positive cell line ZR75-1 
expressed neither ERα nor ERβ. The second is, that although the MTO ERβ cell 
line with ERβ expressed greatly increased transcript, the protein was not 
increased. This is in contrast to work done in other labs where the MTO ERβ off 
showed no ERβ protein expression and the MTO ERβ on had a clearly defined 
band for ERβ expression using a cocktail of 1:1 of the ERβ antibodies 14C8 and 
7B10.7 both from GeneTex (Hodges-Gallagher, Valentine, El Bader, & Kushner, 
2008). Another surprising result was that neither ICI nor E2 decreased the protein 
expression of ERα, but ICI did appear to stabilize ERβ.   
Some of the controversy in the literature comes from the detection of ERβ 
in western blots. We tried three antibodies: GTX70174 did not have any 
detectable bands, PA1-311 detected an antigen with a higher than expected 
molecular weight. PA1-311 antibody also detected antigen in the HeLa cell line, 
which are known to be ERβ negative. PA1-310B detected an antigen with a lower 




its specificity for the ERβ receptor is also questionable due to the lack of a strong 
band in the MTO cells with ERβ overexpression.  Another curiosity is that PA1-
310B indicated strong expression of ERβ protein in the MCF-7 cell line, although 
the ESR2 transcript in this cell line is extremely low. Therefore our confidence 
that this antibody is detecting ERβ is also low.  
It is standard in clinical practice to define treatments for breast cancer 
based on their hormone receptor status. About 15% of breast cancer is classified 
as triple negative, so treatments that rely on hormone receptors are not an option 
for these patients. Also, receptor testing does not take in to account the ER 
subtypes. ERβ is thought to be a tumor suppressor as well as modulate the 
transcriptional effects of ERα. ERβ has been found in triple negative breast 
cancer. In this study we attempted to confirm the presence and the balance of 
the ERα and ERβ in our reference cell lines. This work shows that two TNBC cell 
lines do indeed have ESR2 expression on the mRNA and ERβ protein levels. 
The TNBC lines MDA MB 231 and HCC1937 expressed 182-fold and 24-fold 
more ESR2 than the ESR1 positive cell line T47D (Figure 2.10). These cell lines 
also expressed relatively high ratios (~15 and 8 fold more) of ERβ protein in 
western blots (Figure 2.10) than T47D. Therefore, targeting ERβ may have a 









Figure 2.1 Estrogen Receptor alpha (a) and beta (b) status 
charts from several sources demonstrate conflicts. T47D, 
MCF-7 cells test positive for both ERα and ERβ while MDA MB 231 
and HCC1937 cells could be both ERα positive or negative 
depending on the source. 	
Estrogen Receptor α T47D MCF7 ZR75-1 MDA MB 231
HCC 
1937
Tong et.al., 2002 + + + -
Kao et.al., 2009 + + + - -
Subik et.al., 2010 + + -
Ford et.al., 2011 + + + +
DL Holliday et.al.,2011 + + + +
Estrogen Receptor β T47D MCF7 ZR75-1 MDA MB 231
HCC 
1937
Treeck et al., 2008 + +
Poola et al., 2002 + +
Davies et al., 2004 + + +
Bulzomi et al., 2012 - -












PA1-311   
GTX70174 PA1-310B  GTX112927 
Figure 2.3  Diagram of Estrogen Receptor beta isoforms with 
corresponding antibody location on the receptor. ERβ has 
five mRNA splice variants. ERβ-cx, cannot bind ligand, due to a 
change in helix 12 (LBD), resulting from the alternative splicing of 
exon 8 (Ogawa et al., 1998).  
 
 	
Adapted from Adam W. Nelson, Wayne D. Tilley, David E. Neal, 
and Jason Carroll “Estrogen receptor beta in prostate cancer: 
friend or foe?” Endocr Relat Cancer ERC-13-0508, doi:10.1530/
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ESR2	Repression	by	Doxycycline	in	MTO-ERB	Cells	
Figure 2.4 ESR2 Repression by Doxycycline in MTO-ERβ Cells. 
The cell line MTO-ERβ (MCF7 tet off ERβ) has a repressible 
Estrogen Receptor beta. In the presence of 50ng doxycycline (dox), 
expression from a tet-inducible promoter is reduced. As the 
concentration of dox is reduced to 0.005ng, the expression of ERβ 








Figure 2.5 ESR1 (a) and ESR2 (b) Expression in 
Human Breast Cancer Cell Lines. Expression of the 
receptors is relative to T47D. 	













































Figure 2.6 Western Blot comparing PA1-311 and PA1-310B 
ERβ antibodies. 20μg of whole cell lysate loaded per well. 
Lane 1 on both blots is the molecular weight marker. (a) 
PA1-311 ERβ antibody detected a band at ~69kDa. (b) 































Figure 2.7 Representative western blot for ERα, ERβ and β-
actin. Total proteins were resolved using SDS-PAGE and 
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Figure 2.8 Quantification of ERα, ERβ and β-actin in 
Human Breast Cancer Cell Lines.  Representing four 
(ERα and β-actin) and two (ERβ) separate experiments 
run independently using different samples of the 











Figure 2.9 Relative Ratios of ESR1: ESR2 and ERα: 







































Figure 2.10 Western blot and Quantification of the relative expression of ERα, 
ERβ and β-actin proteins in T47D cells treated with Estrogen Receptor 
agonists (a). Quantification of the western blot measuring the effect of ICI on ERα 
(b), ERβ (c) and β-actin (d) in T47D cells. *p< 0.05	
T47D	control	 T47D	10nm	ICI	 T47D	10nm	E2	 T47D	10nm	ICI	+	10nm	E2	
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COMPARISON OF RESPONSES TO DIFFERENT ESTROGEN RECEPTOR 
AGONISTS IN BREAST CANCER CELL LINES IN VITRO. 
Introduction/Rationale 
 
Only 15-30% of luminal epithelial cells express estrogen receptors. In 
response to estrogens, these cells generate local factors to regulate cell fate and 
the development of neighboring cells.  ER mediated transcription of genes is 
regulated by ligand binding of a specific estrogen receptor agonist (Leitman et al., 
2010; Paruthiyil et al., 2011). Stimulation of ERα, through the binding of its 
agonists PPT or E2, mediates cell proliferation (Helguero, Faulds, Gustafsson, & 
Haldosen, 2005; Sotoca et al., 2008). ERβ expression and agonist stimulation 
slows the growth of cells (Hodges-Gallagher et al., 2008; Paruthiyil et al., 2011). 
When the balance of the receptors in the cell leans towards more ERβ than ERα, 
proliferation is repressed (Gougelet, Mueller, Korach, & Renoir, 2007). I have 
observed that increasing the balance of ERβ expression does abate proliferation 
through my own experience cultivating the MTO ERβ cells without dox when 
compared to MTO ERβ cells maintained in dox.  
Three cell lines stood out as examples of ERα and ERβ expressing, 
predominantly ERα expressing or predominantly ERβ expressing. The 
complement of Estrogen Receptors in cells is important because the ratios of 
receptors influences cell growth (Helguero et al., 2005) as well as the ability of a 




Moretti, Montagnani Marelli, & Limonta, 2015). T47D was chosen because it 
expressed both ERα and ERβ in qPCR and western blots. Western blots using 
the cell line MCF-7 showed that it had ERβ, but mRNA expression suggests that 
MCF-7 is primarily an ERα expressing cell line because little ESR2 is expressed. 
Also, we do not have a lot of confidence in the ERβ antibody (PA1-310B), as 
discussed in chapter 2, therefore we regard MCF-7 as primarily ERα. Finally 
HCC1937 was chosen because both the ERβ protein and the ratio of ESR2: 
ESR1 in qPCR was surprisingly high, which led us to regard it as a predominantly 
ERβ expressing cell line.  
The objectives of these experiments using the cell lines are to compare 
responses in each cell line type (ERα and ERβ expressing, ERα expressing and 
ERβ expressing) to different receptor agonists in terms of proliferation responses 
and potential genome surveillance. ERα and ERβ directs the transactivation of 
estrogen response genes in the cell including genes that modulate proliferation 
and genomic surveillance (Lattrich, Juhasz-Boess, Ortmann, & Treeck, 2008). 
The progesterone receptor is one of the downstream targets of ERα and its 
upregulation is correlated to a ligand-activated ERα (Flötotto et al., 2004; Saji et 
al., 2002). Amphiregulin (AREG) is an important growth factor that is also 
induced by estrogen through ERα stimulated signaling (Ciarloni, Mallepell, & 
Brisken, 2007). This member of the epidermal growth factor (EGF) family signals 
in a paracrine fashion through the EGF receptor to stimulate proliferation. AREG 




mice (Lee et al., 2007; Niemeyer, Spencer-Dene, Wu, & Adamson, 1999). The 
expression of TGFβ2 and CEBPd indicate induction of genomic surveillance. 
Transforming growth factor- beta 2 (TGFβ2) is a cytokine that once bound to its 
membrane receptor, initiates the intercellular recruitment of a complex of 
activated Smad proteins that interact with DNA to transactivate genes involved in 
cell cycle arrest and apoptosis (Massagué, 2008). CEBPd, a member of the 
CCAAT transcription enhancer binding proteins, has been indicated as a good 
prognostic marker for long progression free survival in patients with ERα positive 
breast cancer (Mendoza-Villanueva et al., 2016). Also, in MCF-7 and other breast 
cancer cell lines, CEBPd was also found to promote differentiation and inhibit 
growth through the down regulation of cyclins (Pawar et al., 2010). The 
quantification of these transactivation markers after the acute agonist treatment, 
with different complements of Estrogen Receptors as context, will help elucidate 
ER mediated cell fate. 
Materials and Methods 
 
Cell Culture: All cells were cultured at 37°C and 5% CO2. Each Cell line was 
expanded in their standard Dulbecco’s Modified Eagle’s Medium/Nutrient mixture 
F1-12 Ham (DMEM:F12, Sigma-Aldrich; St. Louis, MO) with 15 mM NaHCO3 and 
25 mM Hepes. Three days before plating for each treatment (in triplicate), the 
media was switched to phenol red-free (prf) DMEM:F12 media with 5% Charcoal 
Stripped Fetal Bovine Serum (CS-FBS, Sigma-Aldrich; St. Louis, MO). Cells were 




Treat; Shirley, MA) at 50-60% confluence in order to achieve optimum 75-80% 
cell density at time of harvest.  One day after plating the serum was reduced to 1 
or 2% CS-FBS. After incubating for 24 hours in 1 or 2% CS-FBS media, cells 
were treated with the agonists at the concentrations indicated (Figure 3.1) in prf 
DMEM:F12 media with 1 or 2% CSS. Cells were treated with either E2 (Sigma 
Aldrich; Cat# E27858), PPT (R&D Systems; Cat#1426-50), ERB041 (R&D 
Systems; Cat# 4276-50 in combination with ICI (Sigma Aldrich; Cat# I4409-
25MG). The cells were harvested for mRNA or lysates after 24 hours of 
treatment. To repress the expression of ERβ in the MCF-7 tet off cells, cells were 
maintained in 50 ng/ml Doxycycline (Dox)(Sigma-Aldrich; St. Louis, MO). 
mRNA isolation and RT-qPCR:  mRNA isolation and RT-qPCR was described 
previously in chapter 2 and primer pairs are listed in Figure 3.2. Gene expression 
is shown relative to an IRC and the two-sided Student’s t-test was used to 
determine differences between each agonist treatment together with ICI against 
the control treated with ICI. P-values of <0.5 (*) was considered significantly 
different; <0.01 (**) considered highly significantly different. Error bars indicate 












Treatment with 10nM ICI 182,780 suggests potential contaminating  
estrogens in cell culture  
 
 Although, there was a significant increase in AREG expression in T47D 
cells treated with Estrogen Receptor agonists E2, PPT and ERB041 compared to 
untreated T47D cells (Figure 3.3 a), treatment with 10nM ICI also significantly 
decreased AREG expression. We found that 1nM E2 treatment as well as all 
doses of PPT significantly increased AREG expression. ERB041 was able to 
increase AREG expression in T47D cells only at the lowest dose (20nM), while 
the higher doses were not significant. Whereas the differences are considered 
significant with the t-test, the fold change increase is small, with between 0.5 to 2 
-fold increments and there was no observable dose dependent effect. We found 
no significant effect in terms of PR expression in MCF-7 cells using the same 
Estrogen Receptor agonists (Figure 3.3 b). However, treatment with 10nM ICI 
also significantly reduced PR expression relative to the untreated control. The 
reduction in expression of AREG and PR expression in the presence of 10nM ICI 
signifies that the culture conditions may contain an unknown estrogenic 
compound that is increasing background AREG and PR expression in the T47D 







Effect of Agonists on gene expression in T47D cells  
 
Because we detected background estrogenic activity that could be 
reduced with 10nM ICI, T47D cells were treated with ICI in conjunction with 
agonists to observe differences in mRNA expression. E2 treatment significantly 
increased the expression of AREG in a dose dependent manner (Figure 3.4 a) 
Although 1nM PPT significantly decreased AREG expression (p=0.03); PPT at 
the highest doses, similar to E2, increased expression of AREG in a dose 
dependent manner. Interestingly, the ERβ agonist, ERB041, significantly 
decreased the expression of AREG in T47D cells, signifying that specific 
activation of ERβ repressed this growth factor. We also analyzed the expression 
of two presumed estrogen regulated genes that could potentially restrict cell 
growth. TGFβ2 was significantly suppressed by E2 (Figure 3.4 b) both at 1nM 
and 10nM E2. The background xenoestrogens in the culture conditions also 
suppressed TGFβ2 expression in the control without ICI, but 10nM ICI releases 
this repression. Low doses of PPT did not repress TGFβ2, but high doses 
(500nM) of PPT significantly repress TGFβ2. Although the expression of TGFβ2 
at the highest ERB041 concentrations (5000nM) was decreased, this may be 
mediated through ERα, rather than ERβ because high concentrations of ERB041 
can have agonist effects on ERα. CEBPd, a potential marker for cell cycle 
inhibition also appeared to be inhibited in the control cells without ICI  and again 
repression was relived by treatment with ICI (Figure 3.4 c). High doses of E2 




doses of the ERα agonists did not significantly change expression. ERB041, the 
ERβ agonist, increased CEBPd expression in T47D cells at 500nM, but not at the 
low or high concentrations.  
Effect of Agonists on gene expression in MCF-7 cells 
 
AREG expression by background estrogens is again blocked by ICI 
treatment in the MCF-7 cells (Figure 3.5 a). E2, at both the 1nM and 10nM 
concentrations, was able to significantly increase AREG expression in a dose 
dependent manner. Interestingly, all three doses of PPT increase the expression 
of AREG in the presence of ICI, but there was a slight decrease in expression, 
from about 20 fold at the highest dose (500nM) to about 17-fold difference 
(50nM) over ICI control. ERB041 at lower doses does not increase expression of 
AREG except at the highest dose (5000nM), however, at high dose (5000nM), 
ERB041 did increase AREG expression significantly, probably because it is able 
to cross-react with ERα. There was no significant TGFβ2 (Figure 3.5 b) or 
CEBPd (Figure 3.5 c) response to the agonists even though the 500nM dose of 
PPT seems to decrease TGFβ2 in MCF-7 cells.   
Effect of Agonists on gene expression in HCC1937 cells 
 
 Next, we used the Estrogen Receptor agonists in HCC1937 cells to 
evaluate their transcriptional responses. There was no significant change is 
expression of AREG (Figure 3.6 a), TGFβ2 (Figure 3.6 b) or CEBPd (Figure 3.6 
c) in response to agonists. Appraisal of the ct values in the qPCR showed that 




large number of outlying ct values as well as a wide range of ct value variance in 
the samples that contributed to the standard error mean. More specifically, the 
variance within treatment groups was mirrored for the gene expression of each of 
the three genes, suggesting that quantification of the RNA was inaccurate. This 
experiment should be repeated because we expect that HCC1937 cells, a 
predominantly ERβ expressing cell line, will not be able to be stimulated by the 
agonists and therefore will not be able to express the ERα regulated gene AREG. 
Whereas, the ERβ agonist ERB041 may increase TGFβ2 and CEBPd 
expression, E2 and PPT should not be able to repress the expression of these 
genes.  
Comparison of AREG, TGFβ2 and CEBPd expression to E2 treatment in  
three cell lines 
 
 Because we chose cell lines to represent three different estrogen receptor 
ratios: (1) expressing both ERα and ERβ, (2) primarily ERα expressing and (3) 
primarily ERβ expressing, we wanted to compare estrogen responses across the 
three cell lines. The ERα and ERβ expressing T47D cells as well as the ERα 
expressing MCF7 cells responded to increasing doses of E2 by expressing 
AREG in a dose dependent manner (Figure 3.7 a). There was a highly significant 
(p< 0.001) difference of in magnitude of AREG expression in both the 1nM and 
20nM E2 treated T47D and MCF7 cells, such that AREG induction by E2 is 




predominantly ERβ expressing cell line HCC1937 had significantly reduced 
AREG expression compared to the cell lines with ERα.  
 Curiously, TGFβ2 was significantly increased in the ERα expressing MCF-
7 cell line in comparison to both the ERα/ERβ expressing cell line T47D an the 
ERβ alone expressing HCC1937 cell line (Figure 3.7 b). There was no difference 
in TGFβ2 expression between T47D cells and HCC1937 cells. Interestingly, 
expression of CEBPd is significantly greater in cells that express ERβ only 
(HCC1937) relative to cells that also express ERα and ERβ (T47D) or ERα 
(MCF7) only (Figure 3.7 c).  
Discussion 
 In our initial experiments, we found that ICI significantly decreased the 
expression of AREG and PR, known ERα responsive genes, suggesting that 
background estrogens were contributing to ERα mediated gene transcription. 
This background activity obscured our ability to measure dose dependent 
responses (AREG) or any responses to agonists at all (PR).   
Finding background estrogen activity in our cell culture system is a hazard 
of working with plastics that may leach xenoestrogens into our cell culture dishes 
(Sax, 2010). These xenoestrogens mimic the activity of naturally occurring 
estrogen to the point of obscuring estrogenic activity in signaling pathways on the 
genomic and non-genomic level (Jeng, Kochukov, & Watson, 2010). This is 
important because cell culture supplies could be contributing to a false result. 




serum, but other factors could be present and should be tested for and controlled 
in estrogen related research models. Our results show that is important to test for 
background estrogen activity in cell culture, and in our case, ICI decreased 
significant background estrogenicity.   
 Using ICI to block background estrogen, we were able to detect significant 
dose-dependent responses to the agonists in the cell line that expressed both 
receptors – T47D. The proliferation maker, AREG, increased by E2 and PPT, but 
was decreased by the ERβ specific agonist ERB041. The expression of growth 
restrictive markers (TGFβ2 and CEBPd) decreased in the presence of E2 and 
PPT. Whereas, ERB041, the ERβ agonist may stabilize or increase expression. 
This indicates that cells that express both ERα and ERβ have a balance of 
proliferation and growth restriction through the two receptors. Further, cells that 
express primarily ERα, like MCF-7, also induce dose dependent increases in 
AREG expression in response to E2 and PPT. However, none of the agonists 
induced any change in expression of TGFβ2 or CEBPd.  
Interestingly, the magnitude of AREG expression in the primarily ERα cell 
line was significantly increased relative to T47D cells which express both 
estrogen receptors. This indicates the importance of the presence of ERβ to 
modulate expression of AREG and proliferation.  Although the analysis for 
HCC1937 needs to be repeated, the current data demonstrates two 
characteristics (1) AREG expression is not induced and is relatively low in the 




magnitude of CEBPd is elevated in the HCC1937 line relative to both ERα and 












Figure 3.1 Agonist Table.  Cell culture treatments for all experiments 







ICI 182,780 10 nM ERα Antagonist 
17 β-estradiol 
(E2) 1ηM  or 10ηM 
Equal agonist/affinity 














   























































Figure 3.3 qPCR for AREG in T47D cells (a) and PR expression MCF7 




























Figure 3.4 RT-qPCR in T47D cells treated with Estrogen Receptor 
agonists  to measure AREG (a), TGFβ2 (b) and CEBPD (c) 

















Figure 3.5 RT-qPCR in MCF7 cells treated with Estrogen 
Receptor agonists to measure AREG (a), TGFβ2 (b) and 
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Figure 3.6 RT-qPCR in HCC1937 cells treated with Estrogen 











Control	 2.60	 14.92	 0.43	
10nM	ICI	 0.90	 0.97	 0.29	
1nM	E2	+	ICI	 1.25	 9.20	 0.39	























Control	 1.30	 5.13487982	 1.933621196	
10nM	ICI	 2.60	 7.346208488	 3.583425817	
1nM	E2	+	ICI	 1.13	 10.16792347	 3.412429879	


























Control	 0.609297518	 1.097195699	 6.542110815	
10nM	ICI	 0.950344886	 0.979201403	 5.268846385	
1nM	E2	+	ICI	 1.221469856	 1.486739253	 5.388308935	

































      T47D                         MCF-7                  HCC1937       !
    ERα/ERβ                         ERα                        ERβ!
      T47D                       MCF-7                  HCC1937       !
    ERα/ERβ                      ERα                        ERβ!
      T47D                         MCF-7                  HCC1937       !








Figure 3.7 Comparison of RT-qPCR expression in three cell lines
* p< 0.05; **p< 0.01	
	
T47D	 MCF7	 HCC1973	
Control	 0.609297518	 1.097195699	 6.542110815	
10nM	ICI	 0.950344886	 0.979201403	 5.268846385	
1nM	E2	+	ICI	 1.221469856	 1.486739253	 5.388308935	








































THE βERKO MOUSE MODEL TO EXPLICATE THE HISTOLOGIC AND GENE 
EXPRESSION PROFILES OF ACUTE AGONIST EXPOSURE IN MOUSE 




Humans and mice have a 95% exon homology and we share many of the 
same genetic diseases (Batzoglou, Pachter, Mesirov, Berger, & Lander, 2000). 
Genetic variation in humans and mice can contribute to the development of, or 
resistance to tumors. Mammary tumor susceptibility is different among women 
and mouse strains.  Some women have an alteration in their tumor suppressor 
proteins, like BRCA1, that allows unrepaired DNA damage that leads to tumor 
formation. This is mirrored in some mouse strains, like BALB/c, which are more 
genetically susceptible to mammary tumorigenesis (Kuperwasser et al., 2000). In 
contrast, the C57BL/6 are resistant to mammary tumors, even in mammary tumor 
induction models including Mouse Mammary Tumor Virus Infection (Okeoma, 
Petersen, & Ross, 2009), gamma-irradiation, and even when the tumor 
suppressor protein p53 is knocked out (Yan et. al., 2010). 
Women vary in their estrogen receptor ratios and in their responses to 
hormones (Dunphy unpublished).  Further, the ratios of estrogen receptors shift 




potentially leading to a shift in the range of ER-hormone mediated responses. 
Mouse strains also exhibit different ER ratios and hormone responses. For 
example, ERα expression is greater in BALB/c when compared to C57BL/6, 
while ERβ expression is similar.  This means that the BALB/c mouse strain has a 
more unfavorable ER ratio, which may potentiate tumorigenesis through ERα 
mediated proliferation (Montero Girard et al., 2007). C57BL/6 mice have reduced 
hormone-induction of RANKL (cytokine of survival, proliferation) and ID2 
(negatively regulates cell differentiation), but elevated p21 (growth arrest) relative 
to BALB/c mice in which p21 is decreased by hormone treatment (Aupperlee et 
al., 2009).  
These experiments are to compare the different responses to various 
estrogen receptor agonists in terms of growth and radiation-induced apoptosis in 
the C57BL/6 mouse mammary gland in the context of different estrogen receptor 
ratios: Wt C57BL/6 with equal ERα: ERβ expression vs. βERKO C57BL/6 with 
ERα expression but no ERβ, and to compare these responses to the BALB/c 
strain which has high ERα: ERβ ratios. The βERKO strain of mice were 
developed by Krege et. al. and have a deleted exon 3, the DNA binding domain 
of ERβ. This deletion results in a non-functional ERβ. The experiments in the 
βERKOs will demonstrate the specificity of the ERβ agonists. 
Materials and Methods 
 
Animal Models:  Mice colonies were maintained in standard cages with ad libitum 




light/dark cycle. ERβ knockout (βERKO) mice were generated by the Korach 
laboratory (Krege et al., 1998) with genetic disruption in Esr2 (B6.129-
Esr2tm1.1Ksk) were used in our experiments. These mice were generously donated 
by Dr. Ken Korach. The knockout allele was maintained on a C57BL/6 
background. Female mice were ear notched for the dual purpose of identification 
and genotyping at the time of weaning, aged 21 days. Ear notch tissue was held 
at -20°C until DNA extraction.  
Preparation of agonist pellets: Pellets were made using silastic tubing (Fisher, # 
11-189-15H) sealed with silicone (DAP Inc, # 070798006881) approximately 1.2 
cm long. These were packed with either cellulose alone as a control or cellulose 
plus one of four compounds: control (Fischer, # AC382312500), E2 (50μg; Sigma 
Aldrich;Cat# E27858), PPT (400μg; R&D Systems, Cat# 1426-50), ERB041 
(400μg; R&D Systems; Cat# 4276-50). The proper ratio of cellulose to hormone 
was combined prior to packing the capsules and then each capsule was packed 
with compound so each would contain the appropriate concentration of the 
specified agonist. The pellets were sterilized with 5kGy gamma irradiation and 
primed in standard phenol red-free DMEM:F12 media (Sigma Aldrich; # D2906) 
for 24 hours prior to implantation.  
βERKO C57BL/6 female mice:  Virgin female mice were ovariectomized at 8-12 
weeks of age and endogenous hormones were allowed to clear for two weeks 
(Figure 4.1). The βERKO mice were treated with individual silastic capsules 




capsule containing cellulose. The silastic capsules were implanted 
subcutaneously into the mouse dorsum and the mice were allowed to be in 
contact with treatments for 96 hrs. Following the treatment period, the animals 
were subjected to 5 Gy whole-body ionizing radiation using a 137Cs source. Mice 
were given an intraperitoneal injection 4 hours post irradiation of 100-200 µl of a 
BrdU (Bromodeoxyuridine) -containing solution (10 mg/ml solution of BrdU in 
sterile 1X PBS). Tissues were harvested 6h post-irradiation. At the end of the 
treatment period the 4th inguinal mammary glands were harvested, the lymph 
nodes removed and the tissues was flash frozen in liquid nitrogen for RNA. Blood 
was collected and allowed to coagulate for serum. The contralateral gland was 
fixed for whole mounts. The third mammary gland and other tissues including 
skin, colon and uteri were collected and were formalin-fixed and paraffin 
embedded for histology. All animal procedures were in accordance with 
institutional and national guidelines for the use of animals and were approved by 
the Institutional Animal Care and Use Committee at the University of 
Massachusetts-Amherst. 
PCR genotyping primers design and amplicon analysis:  DNA from mouse ear 
notch tissue was isolated using KAPA Express Extract enzyme (KAPA 
Biosystems; Boston, MA).   In brief, tissue digestion was achieved using ~1 mm 
mouse tissue, PCR grade H2O, 1U/μl KAPA Express Extract Enzyme and 10X 
KAPA Express Extract Buffer (KAPA Biosystems; Boston, MA) using the 




voretxing, ear notch debris was pelleted. PCR was performed using primer pairs 
listed in Figure 4.2. The typical 11 μL PCR reaction mix contains nuclease free 
water, 1X KAPA2G Fast Genotyping Mix (KAPA Biosystems; Boston, MA) , 0.5 
μM mutant reverse primer, 0.5 μM wild type reverse primer, 0.5 common primer 
and genomic DNA template (<1 μg). The standard PCR condition was as follows: 
95°C for 5 min; 95°C for 15 s, 64°C for 15 s, 72°C for 20 s for 35 cycles; 72°C for 
8 min followed with denaturation for 5 minutes at 95°C. PCR products were 
removed from the thermocycler and maintained at room temperature for at least 
5 minutes allowing for annealing. PCR products were resolved with ethidium 
bromide-stained 1% agarose gel. 
Wholemount Preparation: Whole inguinal mammary glands (gland # 4) were 
spread on glass slides, fixed in Carnoy's solution (60% absolute alcohol, 30% 
chloroform and 10% acetic acid), stained overnight in Carmine alum solution 
(2g/L carmine; 10mM aluminum potassium). Glands were dehydrated in graded 
ethanol, cleared in xylenes and mounted on slides with permount.  
Results 
 
Previous work done in the lab by Erick Roman-Perez compared 
proliferation and radiation-induced apoptosis in C57BL/6 WT and βERKO mice 
that were treated with vehicle control or E2 (50mg) for 4 days. The WT C57BL/6, 
which has both estrogen receptors, had a better apoptotic response than the 




and βERKO mice by including the ER agonists PPT, ERB041 along with E2 and 
a control.   
βERKO mouse genotyping  
 We developed a βERKO mouse specific genotyping protocol using one 
primer set consisting of a mutant reverse, wild type reverse and common primer 
for amplification of mouse ERβ (Figure 4.2). Our primer set was designed to 
produce an ERβ specific PCR product of two DNA fragments with a large size 
difference (~730bp and 407bp). In our experiments we found that the PCR 
resulted in three distinct bands for the heterozygote mice at about 700bp, 600bp 
and 400bp (Figure 4.3). The weaker upper band (~700bp) with heterozygote 
mice is due to the competition of both templates for the same primer pair. Wild 
type mice DNA produced a PCR product at ~600bp and ~400bp. This is in 
contrast to the ERβ null mice which produced two bands, one at ~700bp and the 
other ~600bp. There was a clear distinction between the bands however, and the 
genotyping results were unambiguous.  
βERKO mice database 
In order to track the treatment history of each βERKO mouse test subject 
we developed a cloud-based database (Figure 4.4). Each female mouse received 
an identifying number via ear notch upon weaning. This number was associated 
with the mouse date of birth, ovariectomy date and hormone treatment. A second 




identification of histological samples (mammary gland whole mount, H&E and 
serum), assays (TUNEL and BrdU) as well as RNA samples used for qPCR.   
Areg is upregulated by E2 
Preliminary data from fourth gland mammary tissues in ERβ knockout 
(βERKO) mice show that E2 was able to upregulate the expression of Areg, a 
marker of ERα activated proliferation, about 150-fold over untreated control 
tissues (Figure 4.5). PPT, the ERα selective agonist, failed to increase Areg 
expression in the βERKO mouse mammary tissues. This result is in contrast to 
previous studies in which PPT increased Areg expression to 50% of E2. Finally, 
because Areg is a marker of ERα activation, we do not expect the ERβ agonist to 
work in the βERKO mice for two reasons: (1) βERKO mice do not have a 
functional ERβ receptor and (2) the ERβ agonist ERB041 cannot act through a 
non-functional receptor. In agreement with Areg expression, the mammary 
epithelial ducts are thinner for the control, PPT- or ERB041-reated relative to the 
E2-treated in representative whole mount images (Figure 4.6).    
Discussion 
 
It was expected that E2 would be able to activate ERα in βERKO mice. 
The lack of Areg response to PPT in the mouse tissues was an unexpected 
result. Previous work by Erick Roman-Perez measured Areg in BALB/c mice that 
were treated with vehicle control, E2, PPT and DPN for 4 days. E2 increased the 
expression of Areg almost 200-fold and PPT increased expression almost 150-




sesame seed oil as a carrier for hormone injections and the hormone was 
prepared fresh daily from stock held at -20°C in ethanol. Because daily hormone 
injections with sesame seed oil could be inconsistent and required more animal 
handling, the Lab adapted their hormone delivery methods and began using 
hormone mixed with cellulose packed in silastic capsules. Since then, changes to 
OLAW regulations for animals were implemented that required all surgically 
implanted hormone delivery devices to be sterilized. That meant that PPT, which 
should be stored at -20deg, would be packed into silastic capsules with cellulose 
and irradiated (5 Gy) for 48 hours at room temperature in a Cs-137 irradiator. 
Following sterilization the pellets are placed into priming media overnight at 37oC 
prior to implantation into the mice. It is possible that the extended amount of time 
outside of ideal storage conditions as well as the potential disruption of the 
chemical structure through irradiation may have led to the degradation of PPT. 
The experiments using PPT will need to be repeated after determining methods 




































cDNA Primer Size of 
Product 
Mutant Reverse Mouse ERβ 5’-GTTGGCAGGGAAAGTTGAAAAC-3’ 730 bp 
Wild Type Reverse Mouse ERβ 5’-AGTAACAGGGCTGGCACAAC-3’ 407 bp 
Common Mouse ERβ  5’-TCCCCAAAAGAAACATGTCC-3’  


















+/+	 +/-	-/-	-/-	-/-	-/-	 -/-	+/-	+/-	+/-	 +/-	 	+/-		+/-	
Figure 4.3 Example of genotyping results 	
 	
+/+ Wild type ERβ 	
 -/-  Null (no ERβ)	
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AREG	Expression	in	BERKO	mouse	mammary	gland	in	response	to	
agonists	



























Figure 4.6 Representative βERKO Mouse mammary gland whole 







 Breast cancer cell lines are used as a reference for both agonist induced 
Estrogen Receptor mediated gene expression as well as elucidating potential 
therapeutic targets in human breast cancer (Eric, Jennifer, Fernando, & Jordan, 
2006; Haldosén, Zhao, & Dahlman-Wright, 2014; Helguero, Faulds, Gustafsson, 
& Haldosen, 2005). In this study of ER mediated balance between proliferation 
and growth modulation in human breast cancer, we began by characterizing the 
Estrogen Receptor status as well as the ratio of ERα to ERβ in six immortalized 
breast cancer cell lines: T47D, MCF-7, MDA MB 231, MTO ERβ, HCC1937, 
ZR75-1 and one immortalized “normal” breast cell line 76N tert. We endeavored 
to link the balance of Estrogen Receptors in these cell lines to ER specific 
agonist stimulation in order to measure the response through ER protein and 
gene target expression. For ERα responses we used well-established ERα 
targets AREG and PR. And to gauge the repressive effects of ERβ stimulation we 
used CEBPd and TGFβ2. Then, in order to observe in vitro mammary gland 
responses to ER specific agonists, we utilized an ovariectomized ERβ knockout 
mouse model.  
 After determining the baseline expression of ER through qPCR and 
western blots in our reference breast cancer cell lines, we compared the 
responses to ER agonists. We were able to make several observations about our 




express both ERα and ERβ by gene and protein expression. Our data also 
indicates that E2 and PPT upregulated the ERα responsive gene AREG in a 
dose dependent manner. We observed that ERα expression in T47D cells 
repressed TGFβ2 and CEBPd expression. Secondly, we found that MCF-7 cells 
express primarily ERα. In MCF-7 cells, the ER agonist E2 significantly increased 
the magnitude of AREG expression compared to T47D cells. We believe that in 
MCF-7 cells, with unopposed ERα expression increases the responsiveness of 
the cell to E2-mediated proliferation. Next, we observed that HCC1937 cells 
primarily express ERβ. Also, the HCC1937 cell line expresses high endogenous 
levels of CEBPd, the potential marker for cell cycle arrest, relative to both ERα 
and the ERα/ERβ expressing cell lines.  
Frustratingly, we observed several results that will have to be resolved in 
the future. Among the results is that our western blot data indicate that a reliable 
ERβ antibody remains elusive. Our western blot data is questionable for three 
reasons. First, the MTO ERβ overexpressing and HCC1937 cell lines had 
erroneously low ERβ protein expression despite having high and moderate qPCR 
expression respectively. Secondly, we observed the slow growth pattern of these 
two cell lines, which is typical of ERβ expressing cells, so we are confident that 
they are expressing ERβ protein. And finally, the protein band for the “ERβ” 
antibody observed on the blot was not the correct calculated molecular weight. 
Among the western blot results we were also surprised to find that we may have 




expression observed in this traditionally ERα positive cell line. Another result that 
will need to be addressed is in regard to the in vivo experiments in the βERKO 
mice. Our results indicate that the low expression of PPT induced AREG 
observed in qPCR may be due to the thermo instability of PPT for the extended 
period of time needed for irradiation-based sterilization prior to in vivo testing.  
In the future, our lab will choose new cell lines that express ERα primarily, 
ERβ primarily and express both ERα and ERβ to test responses to Estrogen 
Receptor specific agonists. We will also retry PPT treatments in βERKO mice as 
well as in wild type mice. We will also run qPCR on the harvested βERKO 
mammary tissue in order to determine the expression of CEBPd and TGFβ2.  
To conclude, ERα and ERβ are just parts of the dynamic tension that 
determines breast cancer cell proliferation and cell cycle arrest. Building upon the 
results presented here, we hope to improve our understanding of the Estrogen 
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